Geron

Quote





anonymous said:
Idk, it's crazy to think sales peaking at $45mm a qtr. Seems like they absolutely fumbled the launch, but they'll figure it out eventually.
Click to expand...
The current leadership is killing this company. Several have left in last week everybody is looking. Unattainable goals and clueless leadership. Entire focus is reach and frequency. The stock will drop lower and once the reps leave, backfilling will be impossible as this is a small industry and repa talk. The new leadership they brought in with big stock options are destroying this company.
 


anonymous said:
The current leadership is killing this company. Several have left in last week everybody is looking. Unattainable goals and clueless leadership. Entire focus is reach and frequency. The stock will drop lower and once the reps leave, backfilling will be impossible as this is a small industry and repa talk. The new leadership they brought in with big stock options are destroying this company.
Click to expand...
Come on, it can't be that bad can it? How crazy are the sales targets? They'd have to be next level absurd for reps to just stop trying entirely.
 


anonymous said:
The current leadership is killing this company. Several have left in last week everybody is looking. Unattainable goals and clueless leadership. Entire focus is reach and frequency. The stock will drop lower and once the reps leave, backfilling will be impossible as this is a small industry and repa talk. The new leadership they brought in with big stock options are destroying this company.
Click to expand...
Welp, looks like Chip's out! Wonder if JZ's next.
 


anonymous said:
Come on, it can't be that bad can it? How crazy are the sales targets? They'd have to be next level absurd for reps to just stop trying entirely.
Click to expand...
When the new leadership team keeps telling you that we underperformed at Launch and blames it on the sales team you lose faith in them. We are rare disease and have a very limited indication. What if those new goals aren't aligned with our indication? When you have a leadership team that doesn't actually know the product (As proved on his investor calls) Hiring him created a shitshow and turned a decent culture into a primary care model, you lose faith. This company hired some of the best in the industry and they don't need to be micromanaged, these are the same reps that other companies are begging to have on their team. Those reps also know their worth and due to their history of performance expect reasonable goals and pay for performance. This is a Launch where insurance providers, medicare, medicaid have to load in the system, especially when we launched with a generic code. Doctors have to also understand where they can use it based on our limited indication. The mere fact that many of us were successful with a generic code, shows the quality of reps you have working for you. I can tell you this, these issues can't be fixed with Reach and Frequency!

I'll predict something simple based on my years of successful experience at other companies. This is what's going to happen at this company, unfortunately good reps will leave (Remember, they are in high demand) All reps talk to each other and they know other reps in their geography. When potential candidates call these reps, they will be honest. You know what that answer will be "You don't want to go there, Leadership is clueless and they don't understand the market. Stay away and wait for something else, goals are too high and you are treated like primary care!" So you are still in a launch and can't find mediocre reps to fill the territory. You may get a bunch of primary care reps with little oncology experience who approach the job of stopping by and dropping off literature that never gets back to doctors. Who knows, they may actually respond to your "Reach and Frequency" model.

This company hired reps who are comfortable challenging doctors due to the years of learning Oncology through the years. We have doctors numbers and have access where many in the industry don't. Good luck hitting your number then! I hope you like trying to justify your lack of sales to the street because that's where your headed.
 




anonymous said:
If it is discovered that JZ set the outrageously high sales goals based on the inclusion of 1st line market share, then he should be fired immediately.
Click to expand...
Idiots like JZ have ruined this industry. We price these drugs at a premium and insurance makes sure every i is dotted and every t is crossed. Doctors have been burned through the years of not getting paid for a drug that could buy a new car. Imagine telling a doctor he can use our drug first line, they use it and don't get paid. That rep has just burned their credibility and doctors won't talk to that rep again. That's the importance of good reps, not "reach and frequency" reps. I have had to tell many of my doctors who inquired about specific patients that that is not in our indication.i may have lost a sell but maintained my credibility. I'm also bound by our specific indication as the multiple required compliance trainings. I will not sell off label! When JZ brought in his clueless management team, I'm still bound by the FDA indication.

Now i have a family and I start getting pressure to push this drug with higher goals, pip threats. I've seen it so at this point. I set on my hands and look for another job. Whistleblower lawsuits were based on these scenarios. JZ likes to point fingers and every failure in his years of oharma he blames on the reps. He's a culture destroyer and finger pointer. This company will fail under him.
 


anonymous said:
Idiots like JZ have ruined this industry. We price these drugs at a premium and insurance makes sure every i is dotted and every t is crossed. Doctors have been burned through the years of not getting paid for a drug that could buy a new car. Imagine telling a doctor he can use our drug first line, they use it and don't get paid. That rep has just burned their credibility and doctors won't talk to that rep again. That's the importance of good reps, not "reach and frequency" reps. I have had to tell many of my doctors who inquired about specific patients that that is not in our indication.i may have lost a sell but maintained my credibility. I'm also bound by our specific indication as the multiple required compliance trainings. I will not sell off label! When JZ brought in his clueless management team, I'm still bound by the FDA indication.

Now i have a family and I start getting pressure to push this drug with higher goals, pip threats. I've seen it so at this point. I set on my hands and look for another job. Whistleblower lawsuits were based on these scenarios. JZ likes to point fingers and every failure in his years of oharma he blames on the reps. He's a culture destroyer and finger pointer. This company will fail under him.
Click to expand...
JZ should be fired along JH and DW. Chip was completely absent and gave the keys to the castle to a dishonest moron. Chips gone and so should all of his terrible choices.

BOD - get rid of JZ and JH and DW or get ready to fail even further.
 




anonymous said:
When the new leadership team keeps telling you that we underperformed at Launch and blames it on the sales team you lose faith in them. We are rare disease and have a very limited indication. What if those new goals aren't aligned with our indication? When you have a leadership team that doesn't actually know the product (As proved on his investor calls) Hiring him created a shitshow and turned a decent culture into a primary care model, you lose faith. This company hired some of the best in the industry and they don't need to be micromanaged, these are the same reps that other companies are begging to have on their team. Those reps also know their worth and due to their history of performance expect reasonable goals and pay for performance. This is a Launch where insurance providers, medicare, medicaid have to load in the system, especially when we launched with a generic code. Doctors have to also understand where they can use it based on our limited indication. The mere fact that many of us were successful with a generic code, shows the quality of reps you have working for you. I can tell you this, these issues can't be fixed with Reach and Frequency!

I'll predict something simple based on my years of successful experience at other companies. This is what's going to happen at this company, unfortunately good reps will leave (Remember, they are in high demand) All reps talk to each other and they know other reps in their geography. When potential candidates call these reps, they will be honest. You know what that answer will be "You don't want to go there, Leadership is clueless and they don't understand the market. Stay away and wait for something else, goals are too high and you are treated like primary care!" So you are still in a launch and can't find mediocre reps to fill the territory. You may get a bunch of primary care reps with little oncology experience who approach the job of stopping by and dropping off literature that never gets back to doctors. Who knows, they may actually respond to your "Reach and Frequency" model.

This company hired reps who are comfortable challenging doctors due to the years of learning Oncology through the years. We have doctors numbers and have access where many in the industry don't. Good luck hitting your number then! I hope you like trying to justify your lack of sales to the street because that's where your headed.
Click to expand...
Hiring 50 salespeople was a dumb mistake. The people who could have made the company great left. This company is a complete disaster
 


anonymous said:
Hiring 50 salespeople was a dumb mistake. The people who could have made the company great left. This company is a complete disaster
Click to expand...
"The people who could have made the company great left" BAHAHAHAHAAHAHAHAHA Sound like a disgruntled Geron mgr! Anil and Denise were losers like most of the management team who either try to make sales' job 10x harder or worse sit with their thumbs up their ass while the sales team does the only work in the company. Non-sales people screwed this place up.
 




anonymous said:
If it is discovered that JZ set the outrageously high sales goals based on the inclusion of 1st line market share, then he should be fired immediately.
Click to expand...
Are you serious lol? What on earth are the targets they're setting? 1L mkt share is just pure fantasy, since they seem to be struggling to sell even in the 3L setting.
 


anonymous said:
Idiots like JZ have ruined this industry. We price these drugs at a premium and insurance makes sure every i is dotted and every t is crossed. Doctors have been burned through the years of not getting paid for a drug that could buy a new car. Imagine telling a doctor he can use our drug first line, they use it and don't get paid. That rep has just burned their credibility and doctors won't talk to that rep again. That's the importance of good reps, not "reach and frequency" reps. I have had to tell many of my doctors who inquired about specific patients that that is not in our indication.i may have lost a sell but maintained my credibility. I'm also bound by our specific indication as the multiple required compliance trainings. I will not sell off label! When JZ brought in his clueless management team, I'm still bound by the FDA indication.

Now i have a family and I start getting pressure to push this drug with higher goals, pip threats. I've seen it so at this point. I set on my hands and look for another job. Whistleblower lawsuits were based on these scenarios. JZ likes to point fingers and every failure in his years of oharma he blames on the reps. He's a culture destroyer and finger pointer. This company will fail under him.
Click to expand...
Label is pretty broad. Should be easy to get reimbursed in 2L and 3L pts right? 1L isn't happening, yeah, but it looks like Geron's problem is that they can't sell this thing even in 2L or 3L.
 


Gotta love these dumbass last 2 posts above -- probably 1 idiot. Hey jackhole, stop worrying about the flattening sales and get yourself to the closest ER to replace your leaking butt plug. More pain to follow for you idiot retail investors. Love, Chip
 


anonymous said:
Label is pretty broad. Should be easy to get reimbursed in 2L and 3L pts right? 1L isn't happening, yeah, but it looks like Geron's problem is that they can't sell this thing even in 2L or 3L.
Click to expand...
Pretty broad??? What an idiot, our label is our label, no grey area sounds like the same idiot on the investors call. Here's the issue with JZ when you were asked about any issues you had no answers. We have issues but the problem is that you surrounded yourself with yes men and nobody wants to tell you any issues. Quite honestly you are too stupid to understand them. "Reach and frequency" has never worked, under you, this company will fail.
 


anonymous said:
Are you serious lol? What on earth are the targets they're setting? 1L mkt share is just pure fantasy, since they seem to be struggling to sell even in the 3L setting.
Click to expand...
JZ, JH, DW and our very own compliance officer LM are all complicit in attempting to force unrealistic targets on the entire field. Targets created using 1L market share we are not indicated for. They are now trying to cover up their lies and using intimidation tactics to get the field to comply with their dishonest practices. All of this going on while at the same time JZ has been named in a class action complaint for violations against federal securities law.
 


poor pinhead JZ! might need big Jim to have JZ sit on his knee for the next call so he can whisper the indication into JZ's ear. Dawn's going to learn soon the consequences of the dimbo Jims fing over the sales team.
 


anonymous said:
Pretty broad??? What an idiot, our label is our label, no grey area sounds like the same idiot on the investors call. Here's the issue with JZ when you were asked about any issues you had no answers. We have issues but the problem is that you surrounded yourself with yes men and nobody wants to tell you any issues. Quite honestly you are too stupid to understand them. "Reach and frequency" has never worked, under you, this company will fail.
Click to expand...
So what are the issues? And don't tell me it's the label. The problem isn't that you guys can't sell to 1L or 2L+ non-transfusion dependent patients. The problem is that ya'll aren't even selling well in the 2L+ setting. You guys have a broader label than Luspatercept did in the 2L+ setting at launch. Blaming the label is silly.
 



Write your reply...
Top Bottom
Back
Quote